MergeReference/NN
:/:
A/DT
Tool/NN
for/IN
Merging/JJ
Reference/NN
Panels/NNS
for/IN
HLA/NN
Imputation/NN
./.
====================
Recently/RB
developed/VBD
computational/JJ
methods/NNS
allow/VBP
the/DT
imputation/NN
of/IN
human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
genes/NNS
using/VBG
intergenic/JJ
single/JJ
nucleotide/NN
polymorphism/NN
markers/NNS
./.
====================
To/TO
improve/VB
the/DT
imputation/NN
accuracy/NN
in/IN
HLA/NN
imputation/NN
,/,
it/PRP
is/VBZ
essential/JJ
to/TO
increase/VB
the/DT
sample/NN
size/NN
and/CC
the/DT
diversity/NN
of/IN
alleles/NNS
in/IN
the/DT
reference/NN
panel/NN
./.
====================
Our/PRP$
software/JJ
,/,
MergeReference/NN
,/,
helps/VBZ
achieve/VBP
this/DT
goal/NN
by/IN
providing/VBG
a/DT
streamlined/JJ
pipeline/NN
for/IN
combining/VBG
multiple/JJ
reference/VBP
panels/NNS
into/IN
one/CD
./.
====================
Human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
in/IN
the/DT
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
region/NN
is/VBZ
an/DT
important/JJ
genetic/JJ
factor/NN
for/IN
a/DT
wide/JJ
range/NN
of/IN
human/JJ
diseases/NNS
,/,
such/JJ
as/IN
type/NN
1/CD
diabetes/VBZ
[/(
1/CD
]/)
and/CC
rheumatoid/JJ
arthritis/NN
[/(
2/CD
,/,
3/CD
]/)
./.
====================
In/IN
association/NN
studies/NNS
of/IN
HLA/NN
,/,
it/PRP
is/VBZ
essential/JJ
to/TO
investigate/VB
the/DT
high-resolution/JJ
genotypes/NNS
of/IN
HLA/NN
genes/NNS
./.
====================
However/RB
,/,
genotyping/VBG
HLA/NN
alleles/NNS
in/IN
a/DT
large/JJ
number/NN
of/IN
samples/NNS
can/MD
be/VB
prohibitively/RB
expensive/JJ
due/JJ
to/TO
the/DT
high/JJ
HLA/NN
typing/NN
cost/NN
./.
====================
To/TO
overcome/VB
this/DT
challenge/NN
,/,
imputation/NN
approaches/NNS
have/VBP
been/VBN
recently/RB
developed/VBD
to/TO
impute/VB
HLA/NN
alleles/NNS
from/IN
intergenic/JJ
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
data/NNS
[/(
4-6/CD
]/)
./.
====================
These/DT
approaches/NNS
,/,
of/IN
which/WDT
SNP2HLA/NN
[/(
4/CD
]/)
is/VBZ
widely/RB
used/VBN
,/,
can/MD
impute/VB
high-resolution/JJ
HLA/NN
alleles/NNS
efficiently/RB
and/CC
have/VBP
been/VBN
utilized/VBN
in/IN
a/DT
number/NN
of/IN
large-scale/JJ
fine-mapping/VBG
HLA/NN
analyses/NNS
of/IN
diseases/NNS
[/(
1-3/CD
,/,
7/CD
,/,
8/CD
]/)
./.
====================
Although/IN
the/DT
use/NN
of/IN
imputation/NN
approaches/NNS
has/VBZ
become/VBN
prevalent/JJ
,/,
imputation/NN
errors/NNS
can/MD
always/RB
be/VB
present/JJ
./.
====================
To/TO
reduce/VB
imputation/NN
errors/NNS
,/,
it/PRP
is/VBZ
often/RB
necessary/JJ
to/TO
use/VB
a/DT
large/JJ
reference/VBP
panel/NN
that/DT
can/MD
capture/VB
diverse/JJ
HLA/NN
alleles/NNS
./.
====================
Both/DT
the/DT
size/NN
of/IN
the/DT
panel/NN
and/CC
the/DT
diversity/NN
of/IN
alleles/NNS
can/MD
increase/VB
if/IN
we/PRP
can/MD
use/VB
multiple/JJ
reference/VBP
panels/NNS
at/IN
the/DT
same/JJ
time/NN
./.
====================
However/RB
,/,
in/IN
current/JJ
HLA/NN
imputation/NN
frameworks/NNS
,/,
there/EX
is/VBZ
no/DT
streamlined/JJ
pipeline/NN
for/IN
simultaneously/RB
utilizing/VBG
multiple/JJ
reference/VBP
panels/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
present/VBP
a/DT
software/JJ
package/NN
,/,
MergeReference/NN
,/,
that/DT
merges/VBZ
multiple/JJ
reference/VBP
panels/NNS
in/IN
SNP2HLA/NN
[/(
4/CD
]/)
format/IN
into/IN
a/DT
single/JJ
panel/NN
for/IN
HLA/NN
imputation/NN
./.
====================
By/IN
merging/VBG
multiple/JJ
reference/VBP
panels/NNS
of/IN
similar/JJ
ethnicities/NNS
,/,
we/PRP
can/MD
increase/VB
both/CC
the/DT
sample/NN
size/NN
and/CC
the/DT
allele/NN
diversity/NN
of/IN
the/DT
panel/NN
and/CC
therefore/RB
improve/VBP
the/DT
imputation/NN
accuracy/NN
./.
====================
We/PRP
compared/VBD
the/DT
performance/NN
of/IN
the/DT
Pan-Asian/JJ
reference/VBP
panel/NN
[/(
9/CD
]/)
,/,
the/DT
Korean/JJ
reference/VBP
panel/NN
[/(
10/CD
]/)
,/,
and/CC
the/DT
merged/JJ
reference/VBP
panel/NN
generated/VBN
by/IN
our/PRP$
software/JJ
by/IN
masking/VBG
and/CC
imputing/VBG
the/DT
HLA/NN
alleles/NNS
in/IN
the/DT
HapMap/NN
[/(
11/CD
]/)
Asian/JJ
dataset/NN
./.
====================
The/DT
merged/JJ
panel/NN
achieved/VBD
an/DT
average/NN
4-digit/NN
accuracy/NN
of/IN
six/CD
HLA/NN
genes/NNS
of/IN
93.9/CD
%/NN
,/,
whereas/IN
the/DT
Pan-Asian/JJ
and/CC
the/DT
Korean/JJ
panels/NNS
had/VBD
86.6/CD
%/NN
and/CC
91.5/CD
%/NN
accuracy/NN
rates/NNS
,/,
respectively/RB
,/,
demonstrating/VBG
that/IN
the/DT
simultaneous/JJ
use/NN
of/IN
multiple/JJ
reference/VBP
panels/NNS
improves/VBZ
the/DT
accuracy/NN
./.
====================
MergeReference/NN
is/VBZ
freely/RB
available/JJ
at/IN
http/NN
:/:
//software.buhmhan.com/MergeReference/NN
./.
====================
Step/JJ
1/CD
./.
====================
Extracting/VBG
SNP/NN
and/CC
HLA/NN
allele/NN
data/NNS
====================
Given/IN
two/CD
reference/NN
panels/NNS
to/TO
be/VB
merged/VBN
,/,
we/PRP
extract/VBP
SNP/NN
data/NNS
from/IN
them/PRP
using/VBG
PLINK/NN
[/(
12/CD
]/)
./.
====================
Then/RB
,/,
we/PRP
extract/VBP
HLA/NN
genotype/NN
information/NN
from/IN
the/DT
reference/NN
panel/NN
./.
====================
Because/IN
each/DT
allele/NN
in/IN
an/DT
HLA/NN
gene/NN
is/VBZ
coded/VBN
as/IN
a/DT
binary/JJ
marker/NN
in/IN
SNP2HLA/NN
format/IN
,/,
extracting/VBG
HLA/NN
allele/NN
information/NN
requires/VBZ
the/DT
examination/NN
of/IN
the/DT
entire/JJ
set/NN
of/IN
binary/JJ
markers/NNS
for/IN
an/DT
HLA/NN
gene/NN
./.
====================
We/PRP
use/VBP
our/PRP$
Python/NN
script/NN
to/TO
perform/VB
this/DT
extraction/NN
./.
====================
Step/JJ
2/CD
./.
====================
Combining/VBG
SNP/NN
data/NNS
====================
In/IN
this/DT
step/NN
,/,
we/PRP
combine/VBP
the/DT
SNP/NN
data/NNS
of/IN
the/DT
two/CD
panels/NNS
./.
====================
First/RB
,/,
we/PRP
select/VBP
overlapping/VBG
SNPs/NNS
that/DT
exist/VBP
in/IN
both/CC
panels/NNS
./.
====================
An/DT
alternative/JJ
approach/NN
would/MD
be/VB
to/TO
keep/VB
all/DT
SNPs/NNS
as/IN
partially/RB
missing/VBG
data/NNS
./.
====================
However/RB
,/,
in/IN
this/DT
alternative/JJ
approach/NN
,/,
the/DT
missing/JJ
values/NNS
in/IN
this/DT
step/NN
will/MD
be/VB
automatically/RB
imputed/JJ
in/IN
step/NN
4/CD
and/CC
will/MD
be/VB
used/VBN
as/IN
reference/RB
data/NNS
in/IN
the/DT
imputation/NN
./.
====================
Because/IN
using/VBG
imputed/JJ
data/NNS
as/IN
reference/RB
data/NNS
can/MD
degrade/VB
the/DT
performance/NN
,/,
we/PRP
avoided/VBD
this/DT
alternative/JJ
approach/NN
./.
====================
Second/RB
,/,
we/PRP
check/VBP
and/CC
correct/JJ
the/DT
strand/NN
flips/NNS
of/IN
the/DT
SNPs/NNS
between/IN
the/DT
two/CD
panels/NNS
./.
====================
For/IN
A/T/NN
and/CC
G/C/NN
SNPs/NNS
with/IN
strand/NN
flips/NNS
that/DT
are/VBP
difficult/JJ
to/TO
detect/VB
,/,
we/PRP
use/VBP
frequency/NN
information/NN
./.
====================
Step/JJ
3/CD
./.
====================
Combining/VBG
HLA/NN
data/NNS
====================
We/PRP
combine/VBP
the/DT
HLA/NN
data/NNS
of/IN
the/DT
two/CD
panels/NNS
./.
====================
As/IN
we/PRP
did/VBD
in/IN
step/NN
2/CD
,/,
in/IN
order/NN
to/TO
avoid/VB
using/VBG
imputed/JJ
values/NNS
as/IN
reference/RB
data/NNS
,/,
we/PRP
only/RB
keep/VB
overlapping/VBG
HLA/NN
genes/NNS
that/WDT
exist/VBP
in/IN
both/DT
panels/NNS
./.
====================
Step/JJ
4/CD
./.
====================
Creating/NN
a/DT
merged/JJ
reference/VBP
panel/NN
====================
Given/IN
the/DT
combined/JJ
SNP/NN
data/NNS
from/IN
step/NN
2/CD
and/CC
the/DT
combined/JJ
HLA/NN
data/NNS
from/IN
step/NN
3/CD
,/,
we/PRP
employ/VBP
MakeReference/NN
software/RB
in/IN
the/DT
SNP2HLA/NN
package/NN
[/(
4/CD
]/)
to/TO
construct/VB
the/DT
new/JJ
merged/JJ
reference/VBP
panel/NN
in/IN
SNP2HLA/NN
format/IN
./.
====================
Merging/VBG
Korean/NN
and/CC
Pan-Asian/JJ
panels/NNS
====================
To/TO
test/VB
our/PRP$
MergeReference/NN
software/JJ
,/,
we/PRP
merged/VBD
the/DT
Pan-Asian/JJ
panel/NN
(/(
n=441/NN
)/)
[/(
9/CD
]/)
and/CC
the/DT
Korean/JJ
panel/NN
(/(
n=413/NN
)/)
[/(
10/CD
]/)
./.
====================
The/DT
Korean/JJ
panel/NN
included/VBD
4526/CD
SNPs/NNS
,/,
and/CC
the/DT
Pan-Asian/JJ
panel/NN
included/VBD
4,603/CD
SNPs/NNS
in/IN
the/DT
MHC/NN
region/NN
(/(
chr6:25-34Mb/NN
)/)
./.
====================
The/DT
Korean/JJ
panel/NN
had/VBD
genotype/JJ
information/NN
on/IN
six/CD
HLA/NN
genes/NNS
(/(
A/DT
,/,
B/NN
,/,
C/NN
,/,
DRB1/NN
,/,
DPB1/NN
,/,
and/CC
DQB1/NN
)/)
,/,
and/CC
the/DT
Pan-Asian/JJ
panel/NN
had/VBD
genotype/JJ
information/NN
on/IN
eight/CD
HLA/NN
genes/NNS
(/(
A/DT
,/,
B/NN
,/,
C/NN
,/,
DRB1/NN
,/,
DPA1/NN
,/,
DPB1/NN
,/,
DQA1/NN
,/,
and/CC
DQB1/NN
)/)
./.
====================
After/IN
applying/VBG
MergeReference/NN
,/,
2,995/CD
overlapping/VBG
SNPs/NNS
and/CC
the/DT
genotype/NN
information/NN
of/IN
six/CD
overlapping/VBG
HLA/NN
genes/NNS
were/VBD
left/JJ
./.
====================
Merging/VBG
the/DT
two/CD
panels/NNS
took/VBD
less/RBR
than/IN
10/CD
min/NN
on/IN
a/DT
standard/JJ
computer/NN
(/(
2.7/CD
GHz/NN
Intel/NN
Core/NN
i5/NN
CPU/NN
,/,
8/CD
GB/NN
memory/NN
)/)
./.
====================
Merged/JJ
panel/NN
can/MD
improve/VB
performance/NN
====================
To/TO
compare/VB
the/DT
imputation/NN
accuracy/NN
of/IN
different/JJ
panels/NNS
,/,
we/PRP
used/VBD
the/DT
61/CD
HapMap/NN
Asian/JJ
samples/NNS
from/IN
Beijing/JJ
,/,
China/NN
(/(
CHB/NN
)/)
and/CC
Tokyo/NN
,/,
Japan/NNP
(/(
JPT/NN
)/)
as/IN
benchmark/IN
data/NNS
[/(
11/CD
]/)
./.
====================
We/PRP
masked/VBD
the/DT
HLA/NN
information/NN
of/IN
these/DT
individuals/NNS
,/,
imputed/VBD
them/PRP
,/,
and/CC
compared/VBN
the/DT
imputed/JJ
genotypes/NNS
to/TO
the/DT
true/JJ
genotypes/NNS
./.
====================
We/PRP
evaluated/VBD
three/CD
panels/NNS
:/:
the/DT
Pan-Asian/JJ
panel/NN
,/,
the/DT
Korean/JJ
panel/NN
,/,
and/CC
the/DT
merged/JJ
panel/NN
of/IN
the/DT
two/CD
./.
====================
The/DT
merged/JJ
panel/NN
achieved/VBD
an/DT
average/NN
4-digit/NN
accuracy/NN
of/IN
six/CD
HLA/NN
genes/NNS
of/IN
93.8/CD
%/NN
,/,
whereas/IN
the/DT
Pan-Asian/JJ
and/CC
Korean/JJ
panels/NNS
had/VBD
85.4/CD
%/NN
and/CC
91.5/CD
%/NN
accuracy/NN
rates/NNS
,/,
respectively/RB
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
per-HLA/NN
gene/NN
accuracies/VBZ
are/VBP
described/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
performance/NN
of/IN
the/DT
merged/JJ
panel/NN
was/VBD
equal/JJ
or/CC
superior/JJ
to/TO
that/DT
of/IN
the/DT
individual/JJ
panels/NNS
for/IN
all/DT
HLA/NN
genes/NNS
./.
====================
The/DT
improvement/JJ
in/IN
performance/NN
was/VBD
notable/JJ
for/IN
HLA-DRB1/NN
(/(
Pan-Asian/JJ
,/,
85.2/CD
%/NN
;/:
Korean/NN
,/,
89.3/CD
%/NN
;/:
merged/VBN
,/,
95.1/CD
%/NN
)/)
./.
====================
We/PRP
have/VBP
developed/VBN
MergeReference/NN
,/,
a/DT
software/JJ
package/NN
that/DT
provides/VBZ
a/DT
streamlined/JJ
pipeline/NN
for/IN
combining/VBG
multiple/JJ
reference/VBP
panels/NNS
into/IN
one/CD
for/IN
HLA/NN
imputation/NN
./.
====================
In/IN
a/DT
previous/JJ
study/NN
,/,
Kim/NN
et/FW
al/JJ
./.
====================
[/(
13/CD
]/)
also/RB
evaluated/VBD
the/DT
gain/NN
in/IN
performance/NN
of/IN
merging/VBG
reference/VBP
panels/NNS
for/IN
HLA/NN
imputation/NN
,/,
although/IN
they/PRP
did/VBD
not/RB
provide/VB
a/DT
software/JJ
pipeline/NN
./.
====================
Similar/JJ
to/TO
our/PRP$
work/NN
,/,
their/PRP$
results/NNS
supported/VBD
the/DT
utility/NN
of/IN
merging/VBG
panels/NNS
,/,
particularly/RB
when/WRB
the/DT
ethnicities/NNS
are/VBP
similar/JJ
./.
====================
However/RB
,/,
merging/VBG
Asian/JJ
panels/NNS
with/IN
a/DT
European/JJ
panel/NN
did/VBD
not/RB
provide/VB
better/RBR
performance/NN
for/IN
imputing/VBG
HLA/NN
in/IN
Asian/JJ
samples/NNS
[/(
13/CD
]/)
./.
====================
Therefore/RB
,/,
determining/VBG
whether/IN
merging/VBG
multiple/JJ
panels/NNS
increases/VBZ
the/DT
accuracy/NN
depends/VBZ
on/IN
how/WRB
similar/JJ
the/DT
ethnicities/NNS
of/IN
the/DT
panels/NNS
are/VBP
./.
====================
If/IN
it/PRP
is/VBZ
unclear/JJ
whether/IN
merging/VBG
panels/NNS
would/MD
help/VB
or/CC
not/RB
,/,
it/PRP
can/MD
be/VB
good/JJ
practice/NN
to/TO
evaluate/VB
the/DT
approximate/JJ
accuracy/NN
by/IN
using/VBG
a/DT
public/JJ
dataset/NN
,/,
such/JJ
as/IN
HapMap/JJ
,/,
or/CC
setting/VBG
aside/NN
a/DT
subset/NN
of/IN
the/DT
panel/NN
samples/NNS
as/IN
a/DT
test/NN
dataset/NN
./.
====================
Another/DT
issue/NN
that/IN
can/MD
affect/VB
the/DT
performance/NN
of/IN
the/DT
merged/JJ
panel/NN
is/VBZ
the/DT
sample/NN
size/NN
balance/NN
./.
====================
We/PRP
found/VBD
that/IN
if/IN
one/CD
panel/NN
is/VBZ
much/RB
larger/JJR
(/(
e.g./FW
,/,
by/IN
10-fold/JJ
)/)
than/IN
the/DT
other/JJ
panel/NN
,/,
the/DT
merged/JJ
panel/NN
often/RB
has/VBZ
essentially/RB
the/DT
same/JJ
performance/NN
as/IN
the/DT
single/JJ
large/JJ
panel/NN
./.
====================
In/IN
such/JJ
situations/NNS
,/,
subsampling/VBG
from/IN
the/DT
large/JJ
panel/NN
may/MD
improve/VB
the/DT
balance/NN
of/IN
the/DT
two/CD
panels/NNS
,/,
despite/IN
the/DT
decreased/VBN
sample/NN
size/NN
./.
====================
Further/RB
investigations/NNS
will/MD
be/VB
needed/VBN
to/TO
thoroughly/RB
explore/VB
these/DT
issues/NNS
related/JJ
to/TO
the/DT
gain/NN
in/IN
performance/NN
with/IN
merging/VBG
,/,
and/CC
we/PRP
expect/VBP
that/DT
our/PRP$
software/JJ
pipeline/NN
will/MD
facilitate/VB
such/JJ
explorations/NNS
in/IN
future/JJ
studies/NNS
./.
====================
The/DT
four/CD
steps/NNS
of/IN
MergeReference/NN
for/IN
merging/VBG
two/CD
panels/NNS
into/IN
one/CD
./.
====================
SNP/NN
,/,
single/JJ
nucleotide/NN
polymorphism/NN
;/:
HLA/NN
,/,
human/JJ
leukocyte/NN
antigen/NN
./.
====================
Error/NN
rates/NNS
in/IN
imputing/VBG
HLA/NN
information/NN
on/IN
61/CD
HapMap/NN
CHB/NN
＋JPT/NN
samples/NNS
./.
====================
We/PRP
evaluated/VBD
error/NN
rates/NNS
using/VBG
three/CD
different/JJ
reference/NN
panels/NNS
./.
====================
The/DT
error/JJ
rates/NNS
were/VBD
based/VBN
on/IN
4-digit/NN
imputation/NN
using/VBG
SNP2HLA/NN
and/CC
were/VBD
averaged/VBN
over/IN
six/CD
HLA/NN
genes/NNS
(/(
A/DT
,/,
B/NN
,/,
C/NN
,/,
DRB1/NN
,/,
DPB1/NN
,/,
and/CC
DQB1/NN
)/)
./.
====================
The/DT
bars/NNS
indicate/VBP
95/CD
%/NN
confidence/NN
intervals/NNS
./.
====================
CHB/NN
,/,
Beijing/VBG
,/,
China/NN
;/:
JPT/NN
,/,
Tokyo/NNP
,/,
Japan/NNP
;/:
HLA/NN
,/,
human/JJ
leukocyte/NN
antigen/NN
./.
====================
Per-HLA/NN
gene/NN
imputation/NN
accuracy/NN
in/IN
imputing/VBG
HLA/NN
information/NN
on/IN
61/CD
HapMap/NN
CHB+JPT/NN
samples/NNS
====================
